Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

9.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.2K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

648
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
648
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

386
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
386
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

461
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
461
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A 62-year-old woman with periorbital and preseptal edema and erythema.

Digital journal of ophthalmology : DJO·2026
Same author

Worse Function and Symptoms Among the Most Rural Patients With Advanced Cancer: A Cross-Sectional Analysis.

Cancer medicine·2026
Same author

Factors Associated with Stage at Diagnosis in Pancreatic Cancer: Implications for Precision Screening and Early Detection.

Biomedicines·2026
Same author

Evaluating an online-delivered resistance exercise intervention for racially diverse breast cancer survivors using the RE-AIM framework.

Translational behavioral medicine·2026
Same author

Exercise Counseling and Referral Practices Among Oncology Care Physicians in Latin America: A Multinational Survey Study.

JCO global oncology·2026
Same author

Dysphagia Outcomes Following Chimeric Antigen Receptor T-Cell (CAR-T) Treatment in Patients with Non-Hodgkin Lymphoma.

Cancer investigation·2026

Related Experiment Video

Updated: Nov 25, 2025

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.6K

The exercise in all chemotherapy trial.

Kathryn H Schmitz1, Melanie Potiaumpai1, Erica A Schleicher1

  • 1Penn State Cancer Institute, Penn State College of Medicine, Hershey, Pennsylvania.

Cancer
|December 17, 2020
PubMed
Summary

Integrating exercise professionals into chemotherapy suites is feasible and acceptable for cancer patients. This approach makes exercise a standard part of cancer care, with high completion rates for prescribed exercises.

Keywords:
cancer care deliveryexercise oncologyimplementation sciencemedical oncologysupportive care

More Related Videos

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.4K
The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

19.6K

Related Experiment Videos

Last Updated: Nov 25, 2025

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.6K
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.4K
The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

19.6K

Area of Science:

  • Oncology
  • Exercise Science
  • Cancer Care Integration

Background:

  • International organizations advocate for exercise in oncology care.
  • Feasibility of exercise during systemic chemotherapy remains under-investigated.

Purpose of the Study:

  • To assess the acceptability and feasibility of embedding an exercise professional within chemotherapy infusion suites.
  • To establish exercise as a standard component of cancer treatment.

Main Methods:

  • Screened patients receiving infusion therapy (April 2017-October 2018).
  • Individualized exercise prescriptions based on functional testing.
  • Embedded an exercise professional in the chemotherapy infusion suite.

Main Results:

  • 160 out of 226 approached patients (71%) participated in the trial.
  • High completion rates for prescribed exercises: aerobic (71%), resistance (55%), balance (69%), flexibility (63%).
  • Qualitative data confirmed patient and clinician acceptance; intervention cost ranged from $190.68 to $382.40 per patient.

Conclusions:

  • Embedding exercise professionals in infusion suites is an acceptable and feasible method for standardizing exercise in cancer care.
  • The intervention's cost is comparable to or lower than community programs.
  • Further research should evaluate the impact of colocating exercise professionals with infusion therapy on patient reach.